Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2011 | Original Article

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts

Authors: Stephan Walrand, Raffaella Barone, Stanislas Pauwels, François Jamar

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2011

Abstract

Purpose

The aim of this study was to retrospectively evaluate whether the red marrow (RM) takes up ¹¹¹In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe¹-octreotide and ⁸⁶Y-DOTATOC and to assess the correlation between the RM absorbed doses and platelet count reduction as a biological dose estimate.

Methods

Data from 12 patients who underwent at 24 h p.i. high statistics ¹¹¹In single photon emission computed tomography (SPECT) and ⁸⁶Y positron emission tomography (PET) acquisitions of the chest were analysed. Uptake was measured on >7 cm spine length and converted to total RM uptake using standard RM distribution in man. RM absorbed doses were calculated assuming specific RM uptake and using the plasma and remainder of the body models. RM doses were correlated with the platelet count reduction at 4 weeks. In vitro experiments explored the metabolism of ¹¹¹In-DTPA-D-Phe¹-octreotide and ⁹⁰Y-DOTATOC in plasma.

Results

The correlation between the uptake of both tracers was excellent (R = 0.80), indicating that RM uptake of ⁸⁶Y-DOTATOC reflects a real physiological process and not reconstruction artefacts. The kinetics of ⁸⁶Y-DOTATOC RM activity was different than that in blood and tumours, with no activity at 4 h p.i. indicating that the uptake is not somatostatin receptor dependent. In vitro experiments showed a transchelation of both radiometals to free transferrin that could explain the RM uptake. In patients without chemotherapy and with a normal platelet count recovery, a good correlation (R = 0.96) was found between the RM doses and the platelet count reduction at the nadir.

Conclusion

These experimental facts support the existence of a true RM uptake likely related to transchelation of the radiometal to transferrin. RM uptake correlates well with the observed acute RM toxicity.

Available only for authorised users

Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42:994–1003.PubMedCrossRef

Flux G, Bardies M, Monsieurs M, Savolainen S, Strand SE, Lassmann M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006;16:47–59.PubMed

Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34:1699–700.PubMedCrossRef

Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34:772–86.PubMedCrossRef

Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008;38:321–34.PubMedCrossRef

Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med 2008;38:308–20.PubMedCrossRef

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S–106S.PubMed

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med 2008;49:1884–99.PubMedCrossRef

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S–8S.PubMed

10.

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467–75.PubMed

11.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138–46.PubMedCrossRef

12.

Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, et al. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 1985;26:849–58.PubMed

13.

Cremonesi M, Ferrari M, Chinol M, Stabin MG, Grana C, Prisco G, et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110–20.PubMedCrossRef

14.

Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 1990;10:21–6.PubMed

15.

Wu C, Virzi F, Hnatowich DJ. Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins. Int J Rad Appl Instrum B 1992;19:239–44.PubMed

16.

Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med 1985;26:503–9.PubMed

17.

de Klerk JMH, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996;37:38–41.PubMed

18.

Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27:1084–6.PubMedCrossRef

19.

Langham WH. Radiobiological factors in manned space flight. Washington DC: National Academy Press; 1967.

20.

Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238–50.PubMedCrossRef

21.

Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192–200. doi:10.1007/s00259-010-1549-3

22.

Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354–61.PubMedCrossRef

23.

Walrand SH, van Elmbt LR, Pauwels S. A non-negative fast multiplicative algorithm in 3D scatter-compensated SPET reconstruction. Eur J Nucl Med 1996;23:1521–6.PubMedCrossRef

24.

Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981;26:389–400.PubMedCrossRef

25.

Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17:427–33.PubMedCrossRef

26.

Shih WJ, Van Wyk C. Tc-99m depreotide SPECT demonstrates photon-deficiency in the thoracic vertebrae after adjunct radiation therapy of lung cancer: correlation with MRI and bone scintigraphy. Ann Nucl Med 2003;17:245–8.PubMedCrossRef

27.

Barone R, Walrand S, Leveque P, Pauwels S, Jamar F. Red marrow toxicity after therapy with radiolabelled somatostatin analogues: a possible role of plasma protein binding. Eur J Nucl Med 2003;30:S232.CrossRef

28.

Hauser W, Atkins HL, Nelson KG, Richards P. Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. Radiology 1970;94:679–84.PubMed

29.

Moerlein SM, Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol 1981;8:277–87.PubMedCrossRef

30.

Stern HS, Goodwin DA, Scheffel D, Wagner HN, Kramer HH. In 113m for blood-pool and brain scanning. Nucleonics 1967;25:62–8.

31.

Kroll H, Korman S, Siegel E, Hart HE, Rosoff B, Spencer H, et al. Excretion of yttrium and lanthanum chelates of cyclohexane 1,2-trans diamine tetraacetic acid and diethylenetriamine pentaacetic acid in man. Nature 1957;180:919–20.PubMedCrossRef

32.

Jeffcoat MK, McNeil BJ, Davis MA. Indium and iron as tracers for erythroid precursors. J Nucl Med 1978;19:496–500.PubMed

33.

Goodwin DA, Sundeberg MW, Diamanti C et al. 111In-labeled radiopharmaceuticals and their clinical use. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 80.

34.

Welch MJ, Welch TJ. Solution chemistry of carrier-free indium. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 73.

35.

Breeman WP, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [(177)Lu-DOTA(0),Tyr(3)]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30:312–5.PubMedCrossRef

36.

Oomen SP, van Hennik PB, Antonissen C, Lichtenauer-Kaligis EG, Hofland LJ, Lamberts SW, et al. Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells. Exp Hematol 2002;30:116–25.PubMedCrossRef

37.

Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83:872–5.PubMedCrossRef

Title: Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
Authors: Stephan Walrand
Raffaella Barone
Stanislas Pauwels
François Jamar
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1744-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2011

Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting

Molecular imaging in patients with mood disorders: a review of PET findings

Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level

PET imaging of early response to the tyrosine kinase inhibitor ZD4190

99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology